- Ease in the availability of well-characterized cell banks as per international regulatory guidelines such as FDA-ICHQ5A, Q5B and Q5D to ensure the safety of cell lines for Biotherapeutics development.
- Provide ready to use GMP compliant cell banks for Biopharmaceutical R&D in India. Currently getting a cell lines in India suffers through various shortcomings like very high cost, licensing and royalty’s charges, uncertainty in identity and purity shipping costs, delays in delivery and customs duty payment. Having such facility in India will fill this gap.
- Training of students, technical staffs and scientist with GMP regulations will benefit the existing knowledge gap in this space.
- This will be first of its kind facility in public sector in India. Overall establishment of such facility in Indian institute will largely be in alignment with Make in India and Skill India mandate of Government.
